

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Cofoe Medical Technology Co., Ltd.
可孚醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 1187)

**POLL RESULTS OF THE 2026 SECOND EXTRAORDINARY GENERAL
MEETING**

References are made to the circular (the “**2026 Second EGM Circular**”) and the notice of Cofoe Medical Technology Co., Ltd. (the “**Company**”) dated June 26, 2026, and the notice dated July 3, 2026 in relation to postponement of extraordinary general meeting and change of period of closure of register of members (collectively, the “**2026 Second EGM Notice**”). Unless the context otherwise requires, terms used herein shall have the same meanings as those defined in the 2026 Second EGM Circular. The 2026 second EGM was held on July 20, 2026 at Meeting Room 801, 8/F, Gaoqiao Big Health Medical Zone, No. 426, Section 1, Wanjiali Middle Road, Yuhua District, Changsha City, Hunan Province, the PRC, and was chaired by Mr. ZHANG Min, the chairman of the Board. Directors Mr. ZHANG Min, Mr. ZHANG Zhiming, Mr. XUE Xiaoqiao, Mr. HE Bangjie, Mr. NING Huabo, Ms. SHEN Nan and Mr. ZHOU Rong attended the 2026 second EGM in person or by way of video-conference.

POLL RESULTS OF THE 2026 SECOND EGM

As of the date of the 2026 second EGM, the total number of issued Shares of the Company was 235,897,000 Shares, comprising 208,897,000 A Shares and 27,000,000 H Shares. In particular, based on the A Share capital as at the A Share record date for the 2026 second EGM (i.e., July 14, 2026), 7,195,881 A Shares were repurchased and held by the Company as treasury shares. The above 7,195,881 A Shares held as treasury shares were not counted in the number of Shares entitling their holders to attend and vote on the resolutions (the “**Resolution(s)**”) at the 2026 second EGM, and no voting rights were exercised in respect of such Shares. Accordingly, the total number of Shares entitling the Shareholders to attend and vote for or against the Resolutions at the 2026 second EGM was 228,701,119 Shares (excluding the above 7,195,881 A Shares held as treasury shares), representing approximately 96.95% of the total issued share capital of the Company.

The Shareholders and authorised representatives attending and entitled to vote at the 2026 second EGM held an aggregate of 126,053,929 Shares, representing approximately 55.1173% of the total number of voting Shares of the Company at the date of the 2026 second EGM (excluding the above 7,195,881 A Shares held as treasury shares). In particular, A Shareholders held an aggregate of 125,942,829 Shares, representing approximately 55.0687% of the total number of Shares of the Company entitled to vote at the 2026 second EGM; H Shareholders held an aggregate of 111,100 Shares, representing approximately 0.0486% of the total number of Shares of the Company entitled to vote at the 2026 second EGM.

To the best of the Directors' knowledge, information and belief, no Shareholder was entitled to attend the 2026 second EGM but was required to abstain from voting in favour of the Resolutions under Rule 13.40 of the Hong Kong Listing Rules, and no Shareholder was required to abstain from voting on the Resolutions at the 2026 second EGM under the Hong Kong Listing Rules. No Shares were actually voted on but were excluded from the calculation of voting results on the proposed Resolutions. No Shareholder had stated in any circular of the Company an intention to vote against or abstain from voting on any Resolution at the meeting.

The results of the Resolutions passed by way of poll at the 2026 second EGM are as follows:

SPECIAL RESOLUTION		Valid votes					
		For		Against		Abstain	
		<i>Number of Shares</i>	<i>Percentage</i>	<i>Number of Shares</i>	<i>Percentage</i>	<i>Number of Shares</i>	<i>Percentage</i>
1.	To consider and approve the resolution on the repurchase of the Company's A Shares for cancellation and reduction of registered capital						
1.1	Purpose of the repurchase of A Shares	126,029,249	99.9840%	1,200	0.0010%	23,480	0.0186%
1.2	The repurchase of A Shares meets relevant conditions	126,029,249	99.9840%	1,200	0.0010%	23,480	0.0186%
1.3	Method and price range of the repurchase of A Shares	126,029,249	99.9840%	1,200	0.0010%	23,480	0.0186%
1.4	Type, use, quantity, percentage and total funds of the repurchase of A Shares	126,029,249	99.9840%	1,200	0.0010%	23,480	0.0186%
1.5	Source of funds for the repurchase of A Shares	126,029,249	99.9840%	1,200	0.0010%	23,480	0.0186%
1.6	Implementation period of the repurchase of A Shares	126,024,299	99.9765%	1,200	0.0010%	28,430	0.0226
1.7	Authorisation in connection with the implementation of the repurchase of A Shares	126,029,249	99.9840%	1,200	0.0010%	23,480	0.0186%

ORDINARY RESOLUTION		Valid votes					
		For		Against		Abstain	
		<i>Number of Shares</i>	<i>Percentage</i>	<i>Number of Shares</i>	<i>Percentage</i>	<i>Number of Shares</i>	<i>Percentage</i>
2.	To consider and approve the resolution on the amendments to the Remuneration Management Rules for Directors and Senior Management	126,021,969	99.9746%	4,710	0.0037%	27,250	0.0216%

The above Resolutions numbered 1.1 to 1.7 were passed by a majority of more than two-thirds of the votes, and were accordingly duly passed as special resolutions. The above Resolution numbered 2 was passed by a majority of more than half of the votes, and was accordingly duly passed as an ordinary resolution. For details of the above Resolutions, Shareholders may refer to the 2026 Second EGM Circular and the 2026 Second EGM Notice.

SCRUTINY OF VOTE-COUNTING AND LEGAL OPINION

Poll voting for the Resolutions of the 2026 second EGM was taken in accordance with Rule 13.39(4) of the Listing Rules and the articles of association of the Company (the “**Articles of Association**”). Pursuant to the Listing Rules, Tricor Investor Services Limited acted as the scrutineer for vote-taking of H Shares at the 2026 second EGM. The proceedings of the 2026 second EGM were witnessed by Hunan Qiyuan Law Firm, which issued a legal opinion stating that the convening and conducting procedures of the 2026 second EGM complied with the laws, administrative regulations, rules of procedure of the shareholders’ general meeting and the Articles of Association, the qualifications of the attendees and convener were lawful and valid, the voting procedure conformed to the requirements of the relevant laws, regulations and the Articles of Association, and the voting results were lawful and valid.

By order of the Board
Cofee Medical Technology Co., Ltd.
ZHANG Min
Executive Director and Chairman of the Board

Hong Kong, July 20, 2026

As of the date of this announcement, the board of directors of the Company comprises: (i) Mr. ZHANG Min, Mr. ZHANG Zhiming, Mr. XUE Xiaoqiao and Mr. HE Bangjie as executive Directors; and (ii) Mr. NING Huabo, Ms. SHEN Nan and Mr. ZHOU Rong as independent non-executive Directors.